$1.04
0.00% day before yesterday
Nasdaq, May 30, 10:03 pm CET
ISIN
US22053A1079
Symbol
QNCX
Sector
Industry

Cortexyme, Inc. Stock price

$1.04
-0.06 5.45% 1M
-1.04 50.00% 6M
-0.83 44.39% YTD
+0.21 24.95% 1Y
-1.67 61.62% 3Y
-43.40 97.66% 5Y
-15.96 93.88% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.00 0.00%
ISIN
US22053A1079
Symbol
QNCX
Sector
Industry

Key metrics

Market capitalization $47.29m
Enterprise Value $30.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.47
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-60.93m
Free Cash Flow (TTM) Free Cash Flow $-33.52m
Cash position $31.60m
EPS (TTM) EPS $-1.40
P/E forward negative
Short interest 1.52%
Show more

Is Cortexyme, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Cortexyme, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Cortexyme, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Cortexyme, Inc. forecast:

Buy
100%

Financial data from Cortexyme, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
26% 26%
-
- Research and Development Expense 27 27
152% 152%
-
-61 -61
87% 87%
-
- Depreciation and Amortization 0.18 0.18
47% 47%
-
EBIT (Operating Income) EBIT -61 -61
86% 86%
-
Net Profit -61 -61
100% 100%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cortexyme, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cortexyme, Inc. Stock News

Positive
Seeking Alpha
17 days ago
Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with high price targets, and robust patent protection highlight growing confidence and upside potential. Data readout for the NEAT Phase 3 trial is scheduled for early 2026, with all patients joining the o...
Neutral
Business Wire
19 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quin...
Neutral
Business Wire
about one month ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking ...
More Cortexyme, Inc. News

Company Profile

Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Dirk Thye
Employees 36
Founded 2012
Website quincetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today